BBI-355 / Boundless Bio - LARVOL DELTA

Boundless Bio Announces Portfolio Prioritization and Runway Extension (GlobeNewswire) - "Executive Summary: Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial; Plans to evaluate BBI-355 and BBI-825 as a combination therapy in the POTENTIATE clinical trial, targeting initiation in the second half of 2025."

Trial status • Solid Tumor

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "Enrollment is ongoing in the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept safety and antitumor activity data are expected in the second half of 2025."

P1/2 data • Trial status • Oncology • Solid Tumor

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) - "BBI-355: Enrollment in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a monotherapy and combination agent in patients with locally advanced or metastatic solid tumors with oncogene amplifications is ongoing; Boundless expects to report preliminary clinical proof-of-concept safety and antitumor activity data in the second half of 2025."

P1/2 data • Trial status • Solid Tumor

Clinical Studies Conducted at Florida Cancer Specialists & Research Institute Expanding Treatment Options and Improving Outcomes for Patients with Gastrointestinal and Genitourinary Cancers (PRNewswire) - "Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) is expanding treatment options and contributing to improved outcomes for patients diagnosed with gastrointestinal and genitourinary cancers. FCS research study results are featured at two global gatherings sponsored by the American Society of Clinical Oncology (ASCO)....At the ASCO 2025 Genitourinary Cancers Symposium, Cesar Augusto Perez, MD, as first author, will present results of a Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors."

Clinical data • P1 data • Preclinical • Colorectal Cancer • Gastric Cancer • Urothelial Cancer

Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications. (ASCO-GI 2025) - P1 | "The first ecDNA directed therapy, BBI-355, demonstrated significant synergistic anti-tumor activity in combination with targeted therapies in multiple ecDNA+ oncogene amplified EGC models. BBI-355 alone and in combination with erlotinib/futibatinib was well tolerated. Clinical testing in patients with EGFR and FGFR2 oncogene amplifications is ongoing with a strong rational for EGC."

P1/2 data • Preclinical • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR • FGFR1 • FGFR2

Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355 (ESMO 2024) - P1 | "We developed and validated a novel CTA to detect ecDNA using routine clinical NGS panel data. This CTA will be used to facilitate patient enrollment in Part 3 of the precision medicine POTENTIATE study of BBI-355."

Clinical • Next-generation sequencing • Oncology

Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355 (PRNewswire) - "This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been developed as a clinical trial assay for Boundless Bio's ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355."

P1 data • Oncology • Solid Tumor

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 (PRNewswire) - "SOPHiA GENETICS...announced an update from the Company's work with biopharma company Boundless Bio...The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio's POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process patient samples...Precision is supporting the POTENTIATE clinical trial by adapting its diagnostic workflow to ensure a seamless connection with the SOPHiA DDM Platform. Results from testing of POTENTIATE trial participants' biopsy samples will be used to further analyze clinical activity of the investigational drug BBI-355 in specific patient populations....More information about this collaboration will be provided during the World Clinical Biomarkers & CDx event in Boston on September 5, 2024."

Diagnostic • Licensing / partnership • Trial status • Oncology • Solid Tumor

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results (GlobeNewswire) - P1/2 | N=150 | POTENTIATE (NCT05827614) | Sponsor: Boundless Bio | "Enrollment is progressing in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a single agent and in combination with targeted therapies in patients with locally advanced or metastatic solid tumors with oncogene amplifications. To date, no new safety signals have been observed, and there has been no evidence of combinatorial toxicity in the dose escalation cohorts evaluating BBI-355 in combination with either the EGFR inhibitor erlotinib or the FGFR inhibitor futibatinib...Based on its current projections, the company now anticipates reporting initial clinical proof-of-concept data from POTENTIATE in the second half of 2025...ECHO was previously determined by the FDA to be a non-significant risk device for use as a clinical trial assay (CTA) in the BBI-355 POTENTIATE trial; ECHO has now been analytically validated and institutional review board (IRB)-approved for use as a CTA in the BBI-355..."

Diagnostic • Enrollment status • P1/2 data • Trial status • Oncology • Solid Tumor

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Businesswire) - "Initiated dose escalation in Part 2 of the Phase 1/2 POTENTIATE trial, which evaluates BBI-355 in combination with the EGFR inhibitor erlotinib and BBI-355 in combination with the FGFR inhibitor futibatinib in patients with tumors harboring EGFR or FGFR oncogene amplifications, respectively, to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of each combination regimen....Research and development (R&D) expenses were $13.1 million for the first quarter of 2024, compared to $9.5 million for the same period in 2023. The increase in R&D expenses was primarily due to a $1.8 million increase in the direct program costs for BBI-355, BBI-825, and other development programs..."

Commercial • Trial status • Bladder Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Liposarcoma • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications (AACR 2024) - P1 | "Finally, and for the first time, PD activity of a CHK1 inhibitor in humans was demonstrated by increased pCHK1-S345 expression by immunohistochemistry in skin biopsies from patients enrolled on the POTENTIATE study and treated with BBI-355. In conclusion, pCHK1-S345 is a useful PD biomarker for confirming clinical on-target activity of BBI-355 and may be useful to inform the pharmacologically active range of BBI-355 to support clinical development."

P1/2 data • PK/PD data • Preclinical • Oncology • Solid Tumor

Oral CHK1 inhibitor BBI-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (ecDNA) driven preclinical models (AACR 2024) - P1 | "Oral dosing of BBI-355 provides dose/schedule flexibility to attempt to optimize antitumor activity with a tolerable safety profile in patients with highly aggressive cancers and significant unmet need. The POTENTIATE clinical trial is open and currently enrolling."

Monotherapy • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Sarcoma • Solid Tumor • CHEK1 • EGFR • FGFR2

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Businesswire) - "Abstract Number: 613:...BBI-355 showed inhibition of CHK1 in a host of tumor cell lines and demonstrated in vivo single agent tumor growth inhibition, including complete tumor regressions, across a range of tumor models representing multiple different oncogene amplifications and tumor types. BBI-355 also demonstrated synergistic tumor growth inhibition, including durable regressions, when combined with targeted therapies across multiple oncogene amplified tumor models."

Preclinical • Oncology

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Businesswire) - "Number: 3631:...The findings showed that phosphorylated-CHK1 Ser345 (pCHK1-S345) is a useful pharmacodynamic (PD) biomarker for confirming clinical on-target activity of BBI-355 and could potentially inform the pharmacologically active range of BBI-355 in clinical development. In addition to preclinical data, increased pCHK1-S345 expression by immunohistochemistry in skin biopsies from patients treated with BBI-355 in the ongoing POTENTIATE clinical study were also observed, marking the first, real-time analysis of PD activity from a CHK1 inhibitor in humans."

Biomarker • Preclinical • Oncology

Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024 (Businesswire) - "Boundless Bio...announced multiple upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is being held April 5-10, 2024, in San Diego, CA."

Clinical • Preclinical • Oncology

POTENTIATE: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Boundless Bio | Phase classification: P1/2 ➔ P1 | N=47 ➔ 150 | Trial completion date: Jan 2026 ➔ Sep 2027 | Trial primary completion date: Jan 2025 ➔ Sep 2026

Combination therapy • Enrollment change • Metastases • Phase classification • Trial completion date • Trial primary completion date • Bladder Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Liposarcoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA) (ESMO 2023) - P1/2 | "Conclusions The first ecDNA directed therapy, BBI-355, demonstrated significant anti-tumor activity as a single agent and in combination with targeted therapies in multiple ecDNA+ oncogene amplified tumor models. Clinical testing in patients with oncogene amplification is ongoing."

P1 data • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Sarcoma • Solid Tumor • CHEK1 • FGFR2

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors (Businesswire) - "Boundless Bio...announced that it has entered into a clinical trial collaboration and supply agreement with Taiho Oncology, Inc. (Taiho) for Taiho’s pan-FGFR inhibitor LYTGOBI^® (futibatinib) for use in combination with BBI-355 in a clinical trial of patients with locally advanced or metastatic solid tumors with oncogene amplifications....Under the terms of the agreement, Taiho will provide futibatinib clinical drug supply at no cost for Boundless Bio’s ongoing Phase 1/2 clinical trial (POTENTIATE), which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene amplified solid tumors."

Licensing / partnership • Bladder Cancer • Endometrial Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors (Businesswire) - "Boundless Bio...announced a clinical trial collaboration and supply agreement with Eli Lilly and Company for supply of their CDK4/6 inhibitor Verzenio^® (abemaciclib) for use in combination with BBI-355 in a clinical trial of patients with locally advanced or metastatic solid tumors with oncogene amplifications....Under the terms of the agreement, Lilly will provide abemaciclib clinical drug supply at no cost for Boundless Bio’s ongoing Phase 1/2 clinical trial (POTENTIATE), which will assess BBI-355 in combination with certain selected targeted therapies, including abemaciclib, in patients with specific oncogene amplified solid tumors."

Licensing / partnership • Bladder Cancer • Endometrial Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer (Businesswire) - "Boundless Bio...announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital. Boundless Bio will use the financing to advance BBI-355, the first ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers....The capital raised will fund initial clinical development of BBI-355, as a single agent and in combination with select therapies, for multiple cancer indications with oncogene amplifications being evaluated in the ongoing Phase 1/2 POTENTIATE clinical trial."

Financing • Bladder Cancer • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Liposarcoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification (BioSpace) - '"Memorial Sloan Kettering Cancer Center (MSKCC) is excited to participate in the POTENTIATE study and advance our understanding of ecDNA-driven cancer,' said Alexander Drilon, M.D...'There is a significant need to develop new therapies for patients with cancers enabled by oncogene amplification as there are very few options for these patients.'"

Media quote

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification (Businesswire) - "Boundless Bio...announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614)."

Trial status • Oncology • Solid Tumor

Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition (AACR 2023) - "We identified CHK1 as an ecDNA essential target in a CRISPR genetic screen using a methotrexate-induced ecDNA amplification model in HeLa cancer cells. Oral administration of BBI-cmpd1 resulted in on-target activity against CHK1 and anti-tumor activity in an ecDNA oncogene amplified tumor model in vivo. These findings support the clinical utility of potent, selective, and oral CHK1i to address the significant unmet need driven by ecDNA oncogene amplified cancers."

Oncology • MYC • SOX9

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023 (Businesswire) - "Boundless Bio...will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023....'Our research revealed that ecDNA-enabled cancers have an exquisite reliance on CHK1 to manage intrinsically elevated replication stress, and this important discovery has led to the development of the first ecDTx, BBI-355'."

Clinical • Oncology • Solid Tumor